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Effect of lipid-lowering strategies on tubular cell biology. of renal cysts in both genetic and acquired nephropa-
Background. Interstitial fibrosis and the development of re- thies; tubular cell proliferation is also an early component
nal cysts are crucial phenomena in renal disease progression. of renal lesions in human glomerular and tubular dis-While 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
eases [2]. Growth factors are key mediators in thesereductase inhibitors has been shown to reduce the progression
settings, as they may induce cell proliferation and pro-of several experimental nephropathies, the mechanism of their
potential protective effect remaines unclear. mote cell survival. Epidermal growth factor (EGF) and
Methods. The antiproliferative, apoptotic, and fibrinolytic other tyrosine kinase-dependent signaling pathways acti-
effects of HMG-CoA reductase inhibitors were assessed in vate immediate early genes through the p21ras molecularprimary cultured rat (rPTCs) and mouse proximal tubule cells
switch. Increased expression of c-myc, c-jun, and c-fos(mPTCs), in isolated rat proximal tubules, and in vivo in 5/6
were observed in response to ischemic acute tubularnephrectomized rats (Nx).
Results. In vitro, lovastatin inhibited rPTC proliferation in necrosis or subtotal nephrectomy and in the polycystic
a manner selectively prevented by mevalonate, farnesyl-, or cpk/cpk mouse [3–5]. On the other hand, interstitial fi-
geranylgeranyl-pyrophosphate (FPP or GGPP). Lovastatin re- brosis results from unbalanced extracellular matrixduced membrane-bound p21ras and fetal calf serum-induced
(ECM) production and proteolysis. Interestingly, ECMc-fos and c-jun protein expression. Gel shift assay showed that
products, as well as cytoskeleton components, may par-lovastatin reduced activated protein-1 (AP-1) binding activity.
In vivo, lovastatin inhibited tubular cell proliferation after Nx, ticipate in the control of cell proliferation and apoptosis.
as measured by proliferative cell nuclear antigen staining. Lo- The newly developed cholesterol synthesis antagonists
vastatin-treated mPTCs displayed nucleus cleavage and DNA 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
ladder formation, which were prevented by GGPP. Like C3
reductase inhibitors competitively block production ofexoenzyme, lovastatin induced actin filament disruption, which
mevalonate, the rate-limiting step in isoprenoid and cho-preceded evidence of apoptosis. Lovastatin increased tissue-
type plasminogen activator (PA) and decreased PA inhibitor lesterol synthesis [6]. The modulatory effects of these
activities and antigens; these effects were prevented by mevalo- agents on the cell response to various hormones, growth
nate and GGPP but not FPP, and were reproduced by C3 factors, and mediators have been demonstrated in differ-
exoenzyme in a manner insensitive to GGPP.
ent cell systems. Interestingly, in cultured human mesan-Conclusions. HMG-CoA reductase inhibitors decreased
gial cells, simvastatin inhibited platelet-derived growthproliferation, increased apoptosis, and enhanced fibrinolytic
activity of renal tubular cells via modulation of different iso- factor (PDGF)-induced DNA synthesis and lipopolysac-
prenylated proteins. These effects could participate to reduce charide-induced nuclear factor kB (NF-kB) activation and
the progression of renal diseases. reduced monocyte chemoattractant protein-1 (MCP-1)
production. In cultured rat mesangial cells, simvastatin
inhibited arginine vasopressin-evoked calcium peak and
Tubular cyst formation and interstitial fibrosis are cru- subsequent activation of mitogen-activated protein ki-
cial phenomena in the progressive deterioration of renal nase [7–10]. In the proximal tubule cell line LLCPK1,function in the course of renal diseases. Moreover, inter- simvastatin blocked the stimulatory properties of high-
stitial fibrosis has long been recognized as a main prog- density lipoprotein on the protein content and the mono-
nostic factor regarding renal function outcome in both layer resistance [11]. On the other hand, isoprenylated
human glomerular and tubulointerstitial nephropath- proteins are required for cell cycle progression and the
ies [1]. control of cell growth [12]. Lovastatin and farnesyl-trans-
Sustained tubular cell proliferation and dysregulation ferase antagonists inhibited p21ras isoprenylation and
of programmed cell death are pivotal in the development p21ras-dependent cell growth in vitro and in vivo in p21ras
transformed and untransformed cells [13]. Interestingly,
growth arrest in lovastatin-treated mesangial cells wasKey words: lovastatin, isoprenylation, cell proliferation, apoptosis, fi-
brinolysis. associated with an increased cyclin-dependent kinase
(CDK) regulator p27kip1 and inhibition of PDGF-stimu- 1999 by the International Society of Nephrology
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lated CDK2 and CDK4 activities [14]. Finally, in lovas- FCS-induced rat proximal tubule cells (rPTCs) prolifera-
tatin-treated mesangial cells, the inhibition of Rho pro- tion.
tein geranylgeranylation prevented intracellular actin The effect of lovastatin was prevented by mevalo-
polymerization and induced apoptosis [15]. nate, farnesyl-pyrophosphate (FPP,) and geranylgeranyl-
HMG-CoA reductase inhibitors were shown to reduce pyrophosphate (GGPP), whereas cholesterol and other
progressive glomerulosclerosis and tubulointerstitial fi- products of the mevalonate pathway were inactive. Im-
brosis in different models of renal injury. In Dahl salt- munoblot analysis showed that lovastatin decreased
sensitive rats on a high-salt diet, 22 weeks treatment membrane-bound p21ras and inhibited FCS-induced c-fos
with lovastatin reduced serum cholesterol, albuminuria, and c-jun expression in rPTCs. Furthermore, gel shift
blood pressure, and focal glomerulosclerosis, but did not assay demonstrated the functional impairment of AP-1
alter glomerular hemodynamics [16]. Similarly, in 5/6 DNA binding activity in nuclear extracts from lovastatin-
nephrectomized rats and in obese Zucker rats, HMG- treated cells. Much like the lovastatin effects on up-
CoA reductase inhibition lessened albuminuria and mes- stream components of p21ras activated AP-1 pathway, the
angial matrix expansion and cellularity [17, 18]. Uni- decrease of AP-1 binding activity was totally prevented
nephrectomized nephrotic rats treated for 60 days with by mevalonate.
lovastatin had similar proteinuria but better inulin clear- In vivo, tubular cell proliferation and c-fos protein
ance and less pronounced glomerulosclerosis as com- expression were increased two weeks after nephrectomy,
pared with placebo-treated rats [19]. Importantly, in the as measured by Western blot and immunohistochemical
Han:SPRD rat model of hereditary polycystic kidney analysis of proliferative cell nuclear antigen staining (6.3
disease, lovastatin-treated heterozygous males had milder vs. 1.6 labeled cell per field, P , 0.02). Lovastatin admin-
disease with smaller cysts and lower plasma urea as com- istration (4 mg/kg/d) reduced c-fos protein expression
pared with untreated animals [20]. and tubular cell proliferation (6.3 vs. 3.5 labeled cell per
However, the precise mechanisms of these protective field, P , 0.02) two weeks after nephrectomy.
effects remain unclear. In the rat remnant kidney model, In summary, these results demonstrated that HMG-
the protective effect of lovastatin on renal function two CoA reductase inhibitors were antiproliferative both in
weeks after nephrectomy was associated with elective vitro and in vivo in epithelial tubule cells and that this
vasoconstriction of glomerular efferent vessels and en- effect was exerted via inhibition of the p21ras-activated
hanced reactivity to acetylcholine of afferent glomerular and AP-1–dependent mitogenic cascade (Fig. 1A).
vessels [21]. Lovastatin reduced MCP-1 expression and
macrophage infiltration in nephrotic rats [22]. In the anti- HMG-CoA reductase inhibitors induce apoptosis in
Thy-1.1 rat model of glomerulonephritis, simvastatin proximal tubular cell
suppressed mesangial cell proliferation and macrophage
Twenty-four hour HMG-CoA reductase inhibitor-infiltration and reduced matrix expansion, although it did
treated mouse proximal tubule cells (mPTCs) displayednot affect circulating lipids [23]. Clearly, a large amount
typical features of apoptosis, as evidenced by nucleusof data has now established that HMG-CoA reductase
cleavage after staining with Hoescht 33258, DNA ladderinhibitors could regulate cell functions in vitro and in
pattern on gel electrophoresis, and DNA fragmentationvivo independently from a cholesterol-lowering effect.
as measured by the ratio of fragmented DNA over intactWe evaluated the antiproliferative and apoptotic ef-
DNA following [3H]-thymidine labeling [25]. HFPA re-fects and the fibrinolytic activity of different HMG-CoA
produced the apoptotic effect of lovastatin; conversely,reductase inhibitors in primary cultured proximal tubu-
lovastatin-induced apoptosis was totally prevented bylar cells and in isolated proximal tubules.
GGPP but only partially by FPP.
Actin filament disruption by cytochalasin D or C3 exo-HMG-CoA reductase inhibitors inhibit renal
enzyme, a selective inhibitor of the geranylgeranylatedcell growth
activated Rho protein, induced apoptosis in mPTCs.Treatment of RPT cells during 48 hours with lovas-
Similarly, lovastatin caused early actin filament networktatin, simvastatin, and compactin reduced fetal calf se-
disruption, as evidenced by immunofluorescence studyrum (FCS)-induced [3H]-thymidine incorporation in a
of rhodamine phalloidin staining. This effect was re-concentration-dependent manner, with IC50 values in the
versed by GGPP and preceded evidence of apoptosis.micromolar range [24]. Likewise, lovastatin blocked
Interleukin-1b–converting enzyme inhibitor II, a prote-BrdUrd incorporation, as assessed by immunocytochem-
ase inhibitor, had no effect on the apoptosis induced byical studies. The proliferative effect of EGF was similarly
either cytochalasin D or lovastatin.abolished by lovastatin. Tyrosine kinase and mitogen-
This suggested that in mPTCs, the inhibition of iso-activated protein kinase inhibitors, AP-1 antisense oligo-
prenoid production was instrumental in HMG-CoA re-nucleotides as well as the farnesyl-transferase inhibitor
hydroxy-farnesyl-phosphonic acid (HFPA) decreased ductase inhibitor-induced apoptosis, and that inactiva-
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Fig. 1. Tubular effects of lovastatin. (A) Lo-
vastatin and proliferation. (B) Lovastatin and
apoptosis. (C) Lovastatin and fibrinolysis.
tion of Rho protein and disruption of actin filaments tPA and uPA and a decrease in PA inhibitor-1 (PAI-1)
might play a role in the induction of apoptosis (Fig. 1B). activities. In vitro, supernatants, cytosols, and mem-
branes of renal proximal tubular cells in primary culture
HMG-CoA reductase inhibitors and the tubular had no detectable uPA activity, and lovastatin (0.1 to
fibrinolytic system 10.0 mm) induced an increase in tPA and a decrease in
PAI-1 activities and antigens.Proximal tubules freshly isolated from rats treated for
These effects were selectively prevented by mevalo-two days with lovastatin (4 mg/kg/day) showed increased
nate and GGPP. Accordingly, HFPA did not reproducetissue-type plasminogen activator (tPA) and urokinase
the effect of lovastatin. C3 exoenzyme reproduced the(uPA) activities and antigens [26]. Incubation with lovas-
effect of lovastatin on tPA and PAI-1 activity, and fur-tatin (5 mm) of proximal tubules isolated from untreated
rats induced a time-dependent (6 to 48 hr) increase in thermore, it blocked the preventive effect of GGPP. The
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effect of lovastatin on actin stress fibers network was proliferative effect of lovastatin; on the other hand, dis-
ruption of actin filaments and inhibition of geranylgera-subsequently analyzed. The results of immunofluores-
cence studies demonstrated disruption of cellular actin nylation of Rho protein appear pivotal in the apoptotic
and fibrinolytic activity of lovastatin.stress fibers in lovastatin-treated cells, which was re-
versed by GGPP and reproduced by the C3 exoenzyme.
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